PTC Therapeutics, Inc.

498 articles with PTC Therapeutics, Inc.

• STRIDE Data Show Translarna™ Delays Loss of Ambulation by More Than Five Years in Boys with Nonsense Mutation Duchenne Muscular Dystrophy

  9/20/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented real-world results from the STRIDE patient registry demonstrating that treatment with Translarna™ (ataluren) delays loss of ambulation by more than five years in boys with nonsense mutation Duchenne muscular dystrophy (nmDMD) compared to standard of care (SoC) alone.

• PTC Therapeutics to Host Conference Call to Discuss Results of PTC518 Phase 1 Study for Huntington's Disease Program

  9/20/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a conference call to discuss the positive results from the PTC518 Phase 1 healthy volunteer study.

• PTC Therapeutics Recognizes 2021 STRIVE Awards Recipients for Initiatives Supporting Duchenne Patient Community

  9/7/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the three recipients who will receive funding through the company's STRIVE Awards program.

• PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences - Aug 27, 2021

  8/27/2021

  PTC Therapeutics, Inc. announced that management will present a company overview at the following conferences.

• PTC Therapeutics Announces Waylivra™ Approval in Brazil as First Treatment for Familial Chylomicronemia Syndrome

  8/23/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Brazilian Health Regulatory Agency, ANVISA (Agência Nacional de Vigilância Sanitária), has approved Waylivra™ (volanesorsen) as the first treatment for familial chylomicronemia syndrome (FCS) in Brazil.

• Targeting the Putamen with Gene Therapy Leads to Sustained Improvements in Motor and Non-Motor Functions in Children with AADC Deficiency

  8/23/2021

   PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of a manuscript, "Gene Therapy in the Putamen for Curing AADC Deficiency and Parkinson's Disease," in the European Molecular Biology Organization Journal.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 20, 2021

  8/20/2021

  PTC Therapeutics, Inc. announced that on Aug. 17, 2021, it approved non-statutory stock options to purchase an aggregate of 51,670 shares of its common stock and 19,755 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 48 new employees.

• PTC Therapeutics Provides a Corporate Update and Reports Second Quarter 2021 Financial Results

  7/29/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the second quarter ending June 30, 2021.

• Significant Improvements in Survival and Developmental Milestones Demonstrated in Type 1 SMA Patients Treated with Evrysdi™

  7/28/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that results from Part 2 of the FIREFISH pivotal study were published in the New England Journal of Medicine.

• PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2021 Financial Results

  7/15/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2021 financial results and provide an update on the company's business and outlook on Thursday, July 29, 2021 , at 4:30 p.m. (ET) after the closing of the market.

• Results Add to Body of Evidence Confirming EMFLAZA®'s Benefit Over Prednisone

  6/24/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today presented pooled placebo data from multiple studies in which the results confirmed the clinical benefit of EMFLAZA® (deflazacort) over prednisone for the treatment of Duchenne muscular dystrophy (DMD).

• Evrysdi™ Approved in Japan for the Treatment of Spinal Muscular Atrophy

  6/23/2021

  PTC Therapeutics, Inc. announced that Evrysdi™ was approved in Japan by the Japanese Ministry of Health, Labor and Welfare for the treatment of spinal muscular atrophy.

• PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 15, 2021

  6/15/2021

  PTC Therapeutics, Inc. announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,350 shares of its common stock and 30,835 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 66 new employees.

• Pre-symptomatic Infants with Spinal Muscular Atrophy Achieved Same Motor Milestones as Healthy Children After Treatment with Evrysdi™ in RAINBOWFISH

  6/11/2021

  PTC Therapeutics, Inc. announced positive interim results from the ongoing RAINBOWFISH trial that demonstrated pre-symptomatic infants with spinal muscular atrophy treated with Evrysdi were able to reach motor milestones such as sitting without support, rolling, crawling, standing unaided and walking independently.

• Health and Human Services Expert Mary L. Smith Joins PTC Therapeutics' Board of Directors

  6/9/2021

  Ms. Smith has previously served as the Principal Deputy Director and CEO equivalent at the Indian Health Service, a $6 billion division of the U.S. Department of Health and Human Services and system of hospitals providing healthcare to more than two million Native Americans in the United States.

• PTC Therapeutics Announces Orphan Drug Designations of PTC923 for the Treatment of Hyperphenylalaninemia

  5/26/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that both the United States Food and Drug Administration (FDA) and European Commission (EC) have granted Orphan Drug Designation (ODD) for PTC923 for the treatment of patients with hyperphenylalaninemia. Phenylketonuria (PKU) accounts for 98% of all hyperphenylalaninemia cases and is a metabolic condition that can lead to cognitive disabilities and seizures

• PTC Therapeutics to Participate at Upcoming Virtual Investor Conference

  5/19/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conference: William Blair 41 st Annual Growth Stock Conference Wednesday, June 2 nd at 3:40 p.m. ET

• New Data Shows Devastating Impact of AADC Deficiency on Caregivers

  5/17/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced data from the first study on the impact of caring for a child with the ultra-rare genetic disorder, aromatic L-Amino acid decarboxylase deficiency (AADC-d).

• PTC Therapeutics Provides a Corporate Update and Reports First Quarter 2021 Financial Results

  5/4/2021

  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and financial results for the first quarter ending March 31, 2021.

• PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences - Apr 27, 2021

  4/27/2021

  PTC Therapeutics, Inc. announced that management will present a company overview at the following conferences